DE60135130D1 - Verwendung von substituierten pyrazolen zur behandlung von allergien - Google Patents

Verwendung von substituierten pyrazolen zur behandlung von allergien

Info

Publication number
DE60135130D1
DE60135130D1 DE60135130T DE60135130T DE60135130D1 DE 60135130 D1 DE60135130 D1 DE 60135130D1 DE 60135130 T DE60135130 T DE 60135130T DE 60135130 T DE60135130 T DE 60135130T DE 60135130 D1 DE60135130 D1 DE 60135130D1
Authority
DE
Germany
Prior art keywords
treatment
allergies
substituted pyrazoles
pyrazoles
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135130T
Other languages
English (en)
Inventor
Hui Cai
James P Edwards
Yin Gu
Lars Karlsson
Steven P Meduna
Barbara A Pio
Siquan Sun
Robin L Thurmond
Jianmei Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/927,188 external-priority patent/US6635633B2/en
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE60135130D1 publication Critical patent/DE60135130D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60135130T 2000-09-06 2001-09-05 Verwendung von substituierten pyrazolen zur behandlung von allergien Expired - Lifetime DE60135130D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23040700P 2000-09-06 2000-09-06
US09/927,188 US6635633B2 (en) 2000-08-14 2001-08-10 Substituted pyrazoles
PCT/US2001/027480 WO2002020013A2 (en) 2000-09-06 2001-09-05 A method for treating allergies using substituted pyrazoles

Publications (1)

Publication Number Publication Date
DE60135130D1 true DE60135130D1 (de) 2008-09-11

Family

ID=26924202

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135130T Expired - Lifetime DE60135130D1 (de) 2000-09-06 2001-09-05 Verwendung von substituierten pyrazolen zur behandlung von allergien

Country Status (14)

Country Link
EP (1) EP1315492B1 (de)
JP (1) JP4129391B2 (de)
CN (1) CN1321641C (de)
AT (1) ATE402699T1 (de)
AU (2) AU8873101A (de)
CA (1) CA2421510A1 (de)
DE (1) DE60135130D1 (de)
DK (1) DK1315492T3 (de)
ES (1) ES2309088T3 (de)
HK (1) HK1052881B (de)
MX (1) MXPA03001962A (de)
NZ (1) NZ524682A (de)
PT (1) PT1315492E (de)
WO (1) WO2002020013A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421493A1 (en) * 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
ES2201899B1 (es) * 2002-04-01 2005-06-01 Almirall Prodesfarma, S.A. Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos.
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE602005010698D1 (de) 2004-06-09 2008-12-11 Glaxo Group Ltd Pyrrolopyridinderivate
PE20120508A1 (es) 2009-06-17 2012-05-09 Vertex Pharma Inhibidores de la replicacion de los virus de la gripe
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP6133291B2 (ja) 2011-08-12 2017-05-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾロ［３，４−ｃ］ピリジン化合物と使用方法
SG10201804021TA (en) 2013-11-13 2018-07-30 Vertex Pharma Methods of preparing inhibitors of influenza viruses replication
EP3068776B1 (de) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Hemmer der influenzavirenreplikation
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
DK3860998T3 (da) 2018-10-05 2024-03-25 Annapurna Bio Inc Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet
CN111518019B (zh) * 2019-02-01 2023-10-24 江苏豪森药业集团有限公司 一种棕榈酸帕里哌酮中间体的制备方法
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
JPH0615542B2 (ja) * 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
JP3907220B2 (ja) * 1994-06-30 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 複素環含有化合物
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU7553198A (en) * 1997-06-12 1998-12-30 Sumitomo Pharmaceuticals Company, Limited Pyrazole derivatives

Also Published As

Publication number Publication date
DK1315492T3 (da) 2008-10-13
NZ524682A (en) 2004-11-26
EP1315492B1 (de) 2008-07-30
PT1315492E (pt) 2008-10-01
WO2002020013A3 (en) 2002-06-20
CN1505509A (zh) 2004-06-16
AU8873101A (en) 2002-03-22
CN1321641C (zh) 2007-06-20
HK1052881A1 (en) 2003-10-03
EP1315492A2 (de) 2003-06-04
CA2421510A1 (en) 2002-03-14
ES2309088T3 (es) 2008-12-16
WO2002020013A2 (en) 2002-03-14
AU2001288731B2 (en) 2005-12-15
JP4129391B2 (ja) 2008-08-06
MXPA03001962A (es) 2004-03-26
JP2004508330A (ja) 2004-03-18
AU2001288731B8 (en) 2006-04-13
ATE402699T1 (de) 2008-08-15
HK1052881B (zh) 2009-01-30

Similar Documents

Publication Publication Date Title
DE60136546D1 (de) Methode zum bekämpfen der allergien durch verwendung von substituierten pyrazolen
DE60135130D1 (de) Verwendung von substituierten pyrazolen zur behandlung von allergien
ATE360417T1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
ATE270275T1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5- halogen-pyridinen, verwendbar als cox-2 inhibitoren
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60122171D1 (de) Verwendung von substituierten pyrazolen zur herstellung eines medikaments zur behandlung von allergien
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE502004011486D1 (de) Antioxidationsmittel für organisches material und verfahren zur behandlung desselben
DE60203882D1 (de) Verwendung von 2-amino-1-(4-hydroxy-3-methanesulphonamidophenyl)ethanol zur behandlung von harninkontinenz
NO20033401D0 (no) Kjemiske forbindelser
ATE344666T1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
UA51083A (uk) Спосіб лікування важких інфекційних виразок рогівки

Legal Events

Date Code Title Description
8364 No opposition during term of opposition